Together, these data suggest that COUP-TFII may be important in differentiated ERα-expressing, retinoid-responsive, epithelial breast cancer cells and that reduced COUP-TFII leads to tumor advancement, including endocrine resistance. Here, ESR1 is linked to breast cancer.